|Neuralstem Announces Presentations at Upcoming Scientific Conferences|
|View printer-friendly version|
Following is a schedule of relevant presentations:
Title: “Comprehensive In Vivo Nonclinical Safety Assessment of NSI-189, a Small Molecule New Chemical Entity for the Treatment of Major Depressive Disorder”
Title: "NSI-189, a neurogenic compound enhances short-term and long-term potentiation in C57BL/6 mice and reverses LTP impairment in a mouse model of Angelman Syndrome”
Title: “Durable engraftment, neuronal differentiation of human fetal neural stem cell transplants in penetrating ballistic-like brain injury accompanied by amelioration of cognitive deficits.”
Title: “Induction of immune tolerance by short-course immunosuppression after spinal grafting of allogeneic neural precursors in pigs with previous chronic spinal cord traumatic injury”
Title: “Remyelinating human oligodendrocyte progenitors for regenerative treatment of demyelinating diseases and spinal cord injury”
Neuralstem’s technology enables the generation of small molecule compounds by screening hippocampal stem cell lines with its proprietary systematic chemical screening process. The screening process has led to the discovery and patenting of molecules that
The company has completed Phase 1a and 1b trials evaluating NSI-189, a novel neurogenic small molecule product candidate, for the treatment of major depressive disorder or MDD, and is currently conducting a Phase 2 efficacy study for MDD.
Cautionary Statement Regarding Forward Looking Information:
This news release contains "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "seek" or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain.
Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2015, and filed with the Securities and Exchange Commission (